These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 20022271

  • 1. Guidelines for the restart of imiglucerase in patients with Gaucher disease: recommendations from the European Working Group on Gaucher disease.
    Hollak CE, Aerts JM, Belmatoug N, Bembi B, Bodamer O, Cappellini D, Collin-Histed T, Cox TM, Deegan P, Giraldo P, Hughes D, Lukina E, Manuel J, Michelakakis H, Di Rocco M, Vellodi A, Zimran A.
    Blood Cells Mol Dis; 2010; 44(2):86-7. PubMed ID: 20022271
    [No Abstract] [Full Text] [Related]

  • 2. Recommendations for treating patients with Gaucher disease with emerging enzyme products.
    Cox TM.
    Blood Cells Mol Dis; 2010; 44(2):84-5. PubMed ID: 20022772
    [No Abstract] [Full Text] [Related]

  • 3. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
    Giraldo P, Irún P, Alfonso P, Dalmau J, Fernández-Galán MA, Figueredo A, Hernández-Rivas JM, Julia A, Luño E, Marín-Jimenez F, Martín-Nuñez G, Montserrat JL, de la Serna J, Vidaller A, Villalón L, Pocovi M.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):115-8. PubMed ID: 20934891
    [Abstract] [Full Text] [Related]

  • 4. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
    Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, Mengel E, Michelakakis H, Manuel J, Hrebicek M, Parini R, Reinke J, di Rocco M, Pocovi M, Sa Miranda MC, Tylki-Szymanska A, Zimran A, Cox TM.
    Blood Cells Mol Dis; 2010 Jan 15; 44(1):41-7. PubMed ID: 19804996
    [Abstract] [Full Text] [Related]

  • 5. Short-term withdrawal from imiglucerase: what can we learn from it?
    Hollak CE.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):105-6. PubMed ID: 20684887
    [No Abstract] [Full Text] [Related]

  • 6. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
    Zimran A, Morris E, Mengel E, Kaplan P, Belmatoug N, Hughes DA, Malinova V, Heitner R, Sobreira E, Mrsić M, Granovsky-Grisaru S, Amato D, vom Dahl S.
    Blood Cells Mol Dis; 2009 Jan 15; 43(3):264-88. PubMed ID: 19502088
    [Abstract] [Full Text] [Related]

  • 7. Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.
    Serratrice C, Bengherbia M, Alessandrini M, Grosbois B, Camou F, Pers YM, Bismuth M, Marie I, Belmatoug N, Berger M, Comité d'Evaluation et de Traitement de la maladie de Gaucher.
    Blood Cells Mol Dis; 2014 Jan 15; 53(1-2):94-6. PubMed ID: 24411065
    [No Abstract] [Full Text] [Related]

  • 8. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.
    J Bone Miner Res; 2007 Jan 15; 22(1):119-26. PubMed ID: 17032149
    [Abstract] [Full Text] [Related]

  • 9. The long-term international safety experience of imiglucerase therapy for Gaucher disease.
    Starzyk K, Richards S, Yee J, Smith SE, Kingma W.
    Mol Genet Metab; 2007 Feb 15; 90(2):157-63. PubMed ID: 17079176
    [Abstract] [Full Text] [Related]

  • 10. Early access experience with VPRIV(®): recommendations for 'core data' collection.
    Hughes DA, Al-Sayed M, Belmatoug N, Bodamer O, Böttcher T, Cappellini M, Cohen IJ, Eagleton T, Elstein D, Giraldo P, Jones S, Kaplinsky C, Lund A, Machaczka M, Mengel E, Pastores GM, Rosenbaum H, Sjo M, Tiling N, Tsaftaridis P, Zimran A, Weinreb N.
    Blood Cells Mol Dis; 2011 Aug 15; 47(2):140-2. PubMed ID: 21146428
    [No Abstract] [Full Text] [Related]

  • 11. Reduction in imiglucerase dosage causes immediate rise of chitotriosidase activity in patients with Gaucher disease.
    Chien YH, Lee NC, Tsai FJ, Chao MC, Hwu WL.
    Mol Genet Metab; 2010 Sep 15; 101(1):90-1. PubMed ID: 20580583
    [No Abstract] [Full Text] [Related]

  • 12. Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient.
    Aviner S, Levy Y, Yaniv I, Cohen IJ.
    Blood Cells Mol Dis; 1999 Apr 15; 25(2):92-4. PubMed ID: 10389590
    [Abstract] [Full Text] [Related]

  • 13. Imiglucerase in the treatment of Gaucher disease: a history and perspective.
    Deegan PB, Cox TM.
    Drug Des Devel Ther; 2012 Apr 15; 6():81-106. PubMed ID: 22563238
    [Abstract] [Full Text] [Related]

  • 14. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
    Kishnani PS, DiRocco M, Kaplan P, Mehta A, Pastores GM, Smith SE, Puga AC, Lemay RM, Weinreb NJ.
    Mol Genet Metab; 2009 Apr 15; 96(4):164-70. PubMed ID: 19195916
    [Abstract] [Full Text] [Related]

  • 15. Imiglucerase treatment in Gaucher's disease.
    Shah U, Nadeem N, Husen Y, Fadoo Z.
    J Ayub Med Coll Abbottabad; 2007 Apr 15; 19(2):56-9. PubMed ID: 18183722
    [Abstract] [Full Text] [Related]

  • 16. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
    Hsu CC, Chien YH, Lai MY, Hwu WL.
    J Formos Med Assoc; 2002 Sep 15; 101(9):627-31. PubMed ID: 12645190
    [Abstract] [Full Text] [Related]

  • 17. The management of pregnancy in Gaucher disease.
    Granovsky-Grisaru S, Belmatoug N, vom Dahl S, Mengel E, Morris E, Zimran A.
    Eur J Obstet Gynecol Reprod Biol; 2011 May 15; 156(1):3-8. PubMed ID: 21269752
    [Abstract] [Full Text] [Related]

  • 18. Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: A sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Cappellini MD, Carubbi F, Di Rocco M, Giona F, Giuffrida G.
    Blood Cells Mol Dis; 2023 Jan 15; 98():102705. PubMed ID: 36327675
    [Abstract] [Full Text] [Related]

  • 19. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 15; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 20. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease.
    Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P.
    Am J Hematol; 2005 Nov 15; 80(3):223-9. PubMed ID: 16247743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.